{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:06:03Z","timestamp":1789067163782,"version":"build-2803163510"},"reference-count":42,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,8,14]]},"DOI":"10.2967\/jnumed.126.273266","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:10:21Z","timestamp":1789063821000},"page":"jnumed.126.273266","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy"],"prefix":"10.2967","author":[{"given":"Sofie H.","family":"Tolmeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivakumar","family":"Keerthikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjess","family":"Ayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e1inne","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelyn","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"van Mourik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattakorn","family":"Dhiantravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrisha-Jade","family":"Inderjeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narelle","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Pasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026091011101799000_jnumed.126.273266v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026091011101799000_jnumed.126.273266v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091011101799000_jnumed.126.273266v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091011101799000_jnumed.126.273266v1.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264373"},{"key":"2026091011101799000_jnumed.126.273266v1.5","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2026091011101799000_jnumed.126.273266v1.7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(26)00017-3","article-title":"[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b\/2 study","volume":"27","author":"Sandhu","year":"2026","journal-title":"Lancet Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2026091011101799000_jnumed.126.273266v1.9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026091011101799000_jnumed.126.273266v1.10","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2026091011101799000_jnumed.126.273266v1.11","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026091011101799000_jnumed.126.273266v1.12","doi-asserted-by":"crossref","first-page":"1054497","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"12","author":"Kwan","year":"2022","journal-title":"Front Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun."},{"key":"2026091011101799000_jnumed.126.273266v1.14","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat Med."},{"key":"2026091011101799000_jnumed.126.273266v1.15","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026091011101799000_jnumed.126.273266v1.16","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026091011101799000_jnumed.126.273266v1.17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2025.43.5_suppl.16","article-title":"Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177 Lu-PSMA-617","volume":"43","author":"De Bono","year":"2025","journal-title":"J Clin Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-22-3233","article-title":"PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate-resistant prostate cancer","volume":"29","author":"Gupta","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026091011101799000_jnumed.126.273266v1.19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2021.02.042","article-title":"Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer","volume":"150","author":"Scher","year":"2021","journal-title":"Eur J Cancer."},{"key":"2026091011101799000_jnumed.126.273266v1.20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-024-00520-1","article-title":"Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis","volume":"8","author":"Shen","year":"2024","journal-title":"NPJ Precis Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33393\/jcb.2024.2636","article-title":"Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer","volume":"13","author":"Gupta","year":"2024","journal-title":"J Circ Biomark."},{"key":"2026091011101799000_jnumed.126.273266v1.22","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1200\/JCO.2023.41.16_suppl.5064","article-title":"Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial","volume":"41","author":"Hamid","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04975-9"},{"key":"2026091011101799000_jnumed.126.273266v1.24","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2025.08.015","article-title":"Baseline and early on-treatment circulating tumour DNA fraction are a key prognostic biomarker in metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617","volume":"90","author":"Fettke","year":"2026","journal-title":"Eur Urol."},{"key":"2026091011101799000_jnumed.126.273266v1.26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer."},{"key":"2026091011101799000_jnumed.126.273266v1.27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa095"},{"key":"2026091011101799000_jnumed.126.273266v1.28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2263"},{"key":"2026091011101799000_jnumed.126.273266v1.29","doi-asserted-by":"crossref","first-page":"e2300634","DOI":"10.1200\/PO.23.00634","article-title":"Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study","volume":"8","author":"Raychaudhuri","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","article-title":"ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC class I","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"2026091011101799000_jnumed.126.273266v1.31","doi-asserted-by":"crossref","first-page":"e139333","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J Clin Invest."},{"key":"2026091011101799000_jnumed.126.273266v1.32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","article-title":"Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Pedrani","year":"2024","journal-title":"Eur Urol Oncol."},{"key":"2026091011101799000_jnumed.126.273266v1.33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/ijms26010318","article-title":"The emerging predictive and prognostic role of aggressive-variant-associated tumor suppressor genes across prostate cancer stages","volume":"26","author":"Pedrani","year":"2025","journal-title":"Int J Mol Sci."},{"key":"2026091011101799000_jnumed.126.273266v1.34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02990021","article-title":"Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer","volume":"17","author":"Sasaki","year":"2003","journal-title":"Ann Nucl Med."},{"key":"2026091011101799000_jnumed.126.273266v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100988"},{"key":"2026091011101799000_jnumed.126.273266v1.36","doi-asserted-by":"crossref","first-page":"1148389","DOI":"10.3389\/fmolb.2023.1148389","article-title":"The role of p53 in anti-tumor immunity and response to immunotherapy","volume":"10","author":"Carlsen","year":"2023","journal-title":"Front Mol Biosci."},{"key":"2026091011101799000_jnumed.126.273266v1.37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283"},{"key":"2026091011101799000_jnumed.126.273266v1.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270757"},{"key":"2026091011101799000_jnumed.126.273266v1.39","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7150\/thno.96322","article-title":"Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"14","author":"Slootbeek","year":"2024","journal-title":"Theranostics."},{"key":"2026091011101799000_jnumed.126.273266v1.40","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-021-23394-4","article-title":"Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer","volume":"12","author":"Pereira","year":"2021","journal-title":"Nat Commun."},{"key":"2026091011101799000_jnumed.126.273266v1.41","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-24-1883","article-title":"Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group","volume":"30","author":"Wyatt","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026091011101799000_jnumed.126.273266v1.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265099"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.273266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:10:24Z","timestamp":1789063824000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.273266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":42,"alternative-id":["10.2967\/jnumed.126.273266"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.273266","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}